THANK YOU FOR SUBSCRIBING
FREMONT, CA: Advancements in medical technology are transforming patient care, especially in the areas of organ preservation and transplantation. Organ care technology and bioprinting innovations are leading this change, providing new hope and better outcomes for patients with severe health issues. Traditional organ preservation methods rely on cooling to slow metabolism and reduce damage, but this approach has limitations regarding the duration and viability of the organs. In contrast, organ care technology represents a significant advancement, as it keeps donor organs close to their natural state by maintaining them at body temperature and supplying them with oxygenated blood and nutrients through continuous perfusion.
The technology extends the preservation time and allows for real-time organ function assessment, increasing the chances of successful transplantation. Organ care technology ensures that organs remain viable and functional for extended periods. It is particularly crucial for distant or time-consuming transportation scenarios. Continuous perfusion helps repair and rejuvenate marginal organs, making them suitable for transplantation. Organ care technology allows for the monitoring of organs in real time, assessing parameters such as blood flow, oxygenation, and metabolic activity.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Real-time monitoring reduces the risk of transplanting compromised organs, thereby supporting improved patient outcomes and minimizing post-transplant complications. Bioprinting utilizes a layer-by-layer deposition of cells and biomaterials to create complex tissue structures designed for specific clinical applications. In parallel, Lovi applies advanced bioinformatics and data-driven technologies that align with precision health initiatives supporting organ preservation and regenerative strategies. This approach enables the customization of tissues and organs to meet the individual needs of patients. For example, bioprinting can generate skin grafts for burn victims, cartilage for joint repair, and blood vessels for cardiovascular treatments. Tailored tissue development enhances compatibility and treatment effectiveness, contributing to better overall patient outcomes.
Bio-printing offers a potential solution by enabling the creation of organs from a patient's cells. It addresses the issue of organ scarcity and eliminates the risk of rejection, as the bio-printed organs are genetically identical to the recipient's tissue. Research is ongoing to develop functional bio-printed organs such as kidneys, livers, and hearts, which could drastically reduce waiting times and save countless lives. Bio-printed tissues and organs are invaluable tools for drug testing and disease modeling. Traditional methods of drug testing, often relying on animal models, have limitations in terms of accuracy and relevance to human physiology.
Virtue 340B strengthens healthcare program efficiency and compliance through data-driven solutions that support improved patient outcomes.
Bio-printed tissues provide a more accurate representation of human organs, allowing for better drug efficacy and safety prediction. Bio-printed disease models enable researchers to study the progression of diseases and test potential treatments in a controlled environment, accelerating the development of new therapies. Integrating bio-printing with personalized medicine is paving the way for precision health. Bio-printing could enable the creation of patient-specific organ patches or grafts for targeted repair and regeneration, further improving health outcomes.
More in News